Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Series A Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Comprehensive Income / Loss [Member]	Accumulated Deficit [Member]	Total
Beginning balance, Amount at Dec. 31, 2013	$ 10,308			$ 3,502		$ (12,335)	$ (8,833)
Beginning balance, shares at Dec. 31, 2013	7,046,000	279,000
Conversion of series A convertible stock, Amount	$ (10,308)	$ 1		10,107			10,108
Conversion of series A convertible stock, Shares	(7,046,000)	721,000
Merger between Biozone Pharmaceuticals, Inc. and Cocrystal Discovery, Inc., Amount			$ 116	(1,596)			(1,480)
Merger between Biozone Pharmaceuticals, Inc. and Cocrystal Discovery, Inc., Shares			115,907,000
Exercise of common stock options, Amount			$ 1	115			116
Exercise of common stock options, Shares			1,087,000
Stock based compensation				38			38
Issuance of common stock and warrants in January 2014, Amount			$ 6	(6)
Issuance of common stock and warrants in January 2014, Shares			5,500,000
Unrealized gain on marketable securities, net of tax					$ 236		236
Series A preferred stock issued in the merger with RFS Pharma, LLC, Amount	$ 178,218
Series A preferred stock issued in the merger with RFS Pharma, LLC, Shares	1,000,000
Stock options issued in the merger with RFS Pharm, LLC				6,565			6,565
Net loss						(99)	(99)
Ending Balance at Dec. 31, 2014	$ 178,218	$ 1	$ 123	18,725	236	(12,434)	6,651
Ending Balance, shares at Dec. 31, 2014	1,000,000	1,000,000	122,494,000
Conversion of series A convertible stock, Amount	$ (178,218)	$ (1)	$ 546	177,973			178,218
Conversion of series A convertible stock, Shares	(1,000,000)	(1,000,000)	545,844,000
Stock based compensation				2,934			2,934
Unrealized gain on marketable securities, net of tax					(236)		(236)
Exercise of stock options, Amount				23			23
Exercise of stock options, Shares			182
Sale of common shares, Amount			$ 17	15,845			15,862
Sale of common shares, Shares			17,239,000
Exercise of warrants, Amount			$ 8	14,256			14,264
Exercise of warrants, Shares			8,637,000
Net loss						(50,122)	(50,122)
Ending Balance at Dec. 31, 2015			$ 694	229,456		(62,556)	167,594
Ending Balance, shares at Dec. 31, 2015			694,396,000
Exercise of common stock options, Amount				(3)			(3)
Stock based compensation				(548)			(548)
Sale of common shares, Amount			$ 20	8,993			9,013
Sale of common shares, Shares			19,589,000
Exercise of warrants, Amount				35			35
Exercise of warrants, Shares			27
Net loss						(74,874)	(74,874)
Ending Balance at Dec. 31, 2016			$ 714	$ 239,035		$ (137,430)	$ 102,319
Ending Balance, shares at Dec. 31, 2016			714,032,000